We typically target companies with the following attributes:

• Innovative companies with differentiated products that address unmet medical needs, improve patient outcomes and reduce overall healthcare expenditures.

• Products with high gross margin potential and existing reimbursement or pathway to reimbursement coverage.

• Compelling clinical data and limited competition.

Downside protection

• Significant collateral value, including intellectual property.

• Liquidity to fund the business plan to profitability.

• Experienced management team with demonstrated track record of successful product launches and shareholder value creation.

• Private companies with established venture capital investors and public companies with access to capital markets.

• Uses of proceeds that increase collateral value such as acquisition, expansion of commercial infrastructure, product launches and clinical development of breakthrough technologies.

The typical investment size is $20-$100 million.

We typically target companies with the following attributes:

• Proven technology with mission critical offerings.

• Commercial-stage companies with high gross margin.

• Recurring revenue and “sticky” customer relationships, high switching cost and low customer churn.
  
  

Downside protection

• Significant collateral value, including intellectual property.

• Liquidity to fund the business plan to profitability.

• Uses of proceeds that increase collateral value such as acquisition, expansion of commercial infrastructure, product launches and development of breakthrough technologies.

• Experienced management team with demonstrated track record of product launches and shareholder value creation.

• Private companies with established venture capital investors and public companies with access to capital markets.

The typical investment size is $20-$50 million.

Equity

The equity investment strategy is an extension of our existing debt strategy and reserved for opportunities where we have the greatest conviction to create differentiated value. We combine deep industry expertise and a rigorous evaluation process to identify technologies and companies that can drive critical change and have the potential to create significant value.

We typically target companies with the following attributes:

• Breakthrough technologies that address unmet medical needs with large market potential, improve patient outcomes and reduce overall healthcare expenditures.

• Crossover investment opportunities with significant potential for value creation with “line-of-sight” to an exit in the near term.

• Strategic interest from potential buyers.

The typical investment size is $2-$10 million.